Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 8/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RGS12 | O14924 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753884 | 1.00 | SLC9A3 (0.57) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL977588 | 1.00 | SLC9A3 (0.57) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL5630176 | 1.00 | SLC9A3 (0.57) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| Hydrochloric Acid SCHEMBL6496992 | 0.99 | SLC9A3 (0.56) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL980548 | 0.90 | SLC6A2 (0.49) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL13911066 | 0.85 | SLC6A2 (0.50) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL13449755 | 0.84 | SLC9A3 (0.54) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2568332 | 0.82 | SLC9A3 (0.67) | SLC9A3SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL977341 | 0.82 | SLC9A3 (0.39) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL978750 | 0.82 | SLC9A3 (0.39) | SLC9A3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613600-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-1794128-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND A MEDICAMENT CONTAINING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-7790742-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions thereof, methods for their preparation and therapeutic use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1838315-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | sanofi-aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| US-20070225323-A1 | SUBSTITUTED 4-PHENYLTETRAHYRDOISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS THEREOF, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-27 | — | — | US | disclosed |
| US-7241775-B2 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1794128-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND A MEDICAMENT CONTAINING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006074813-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI-AVENTIS (DE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006032372-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND A MEDICAMENT CONTAINING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | CYP27A1, CYP11B2, CYP7A1 | SLC9A3 4035/4885SLC6A2 1036/4885SLC6A4 1064/4885 |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | SLC9A3 2159/4885SLC6A2 651/4885SLC6A4 374/4885 |
| US-20070225323-A1 | SUBSTITUTED 4-PHENYLTETRAHYRDOISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS THEREOF, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USE | SLC10A1, SLC9A3, NHERF1 | SLC9A3 2/4885SLC6A2 14/4885SLC6A4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.